Academic Journal
Longitudinal Blood Biomarker Trajectories in Preclinical Alzheimer’s Disease
| العنوان: | Longitudinal Blood Biomarker Trajectories in Preclinical Alzheimer’s Disease |
|---|---|
| المؤلفون: | Yakoub, Yara, Ashton, Nicholas J., Karikari, Thomas K, Strikwerda‐Brown, Cherie, Montoliu‐Gaya, Laia, Meyer, Pierre‐François, St‐Onge, Frederic, Schöll, Michael, Breitner, John, Zetterberg, Henrik, Blennow, Kaj, Poirier, Judes, Villeneuve, Sylvia |
| المصدر: | Alzheimer's & Dementia ; volume 18, issue S1 ; ISSN 1552-5260 1552-5279 |
| بيانات النشر: | Wiley |
| سنة النشر: | 2022 |
| المجموعة: | Wiley Online Library (Open Access Articles via Crossref) |
| الوصف: | Background Blood‐biomarkers of Alzheimer’s disease (AD) pathology have been investigated cross‐sectionally in heterogenous AD cohorts and have been shown to detect underlying AD pathology, even at preclinical stages. However, longitudinal studies, including serial blood‐biomarker measurements, are needed to better understand whether these markers could help monitor disease progression. We aimed to assess blood‐biomarkers temporal trajectories in cognitively unimpaired older adults at different pathological stages as assessed by positron emission tomography (PET). This may provide insight into dynamic changes of these biomarkers beginning prior to abnormality on PET. Method We included a subset of 126 cognitively unimpaired older adults from the Prevent‐AD cohort. Blood was drawn from baseline up to four‐year follow‐up visits. We measured Aβ 42 /Aβ 40 ratio, pTau181 and pTau231 using novel single molecular array (Simoa). All participants completed Aβ ( 18 F‐NAV4694) and tau ( 18 F‐flortaucipir) PET scans, which were mostly performed at the latest blood collection timepoint. Aβ positivity was defined by global neocortical Aβ‐PET retention (SUVR cut‐off = 1.29), and tau‐PET positivity by entorhinal cortex flortaucipir binding (SUVR cut‐off = 1.23). Using these thresholds, 82 subjects were classified as A‐T‐, 29 as A+T‐, and 15 as A+T+. Linear mixed effects models were used to assess differences in the longitudinal rate of change in plasma biomarkers between the groups. Result Amyloid‐PET‐positive individuals showed elevated levels of pTau181, and pTau231 and lower levels of Aβ 42/40 when compared with amyloid‐PET‐negative participants. Plasma pTau181 levels showed a greater increase over time in the A+T+ group when compared with the A‐T‐ group (p = 0.01; Figure 1 ). Overall, the A+T‐ and A+T+ groups had lower levels of plasma Aβ 42/40 compared with the A‐T‐ group (p = 0.05, p = 0.0189; Figure 2 ), and the A+T‐ group had higher pTau231 compared with A‐T‐ participants (p = 0.0006; Figure 3 ). Longitudinal ... |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| DOI: | 10.1002/alz.064811 |
| الاتاحة: | http://dx.doi.org/10.1002/alz.064811 https://onlinelibrary.wiley.com/doi/pdf/10.1002/alz.064811 https://onlinelibrary.wiley.com/doi/full-xml/10.1002/alz.064811 |
| Rights: | http://onlinelibrary.wiley.com/termsAndConditions#vor |
| رقم الانضمام: | edsbas.817A9B35 |
| قاعدة البيانات: | BASE |
| DOI: | 10.1002/alz.064811 |
|---|